Skip to content
Toggle Navigation
HOME
PIPELINE
LP-410 for Oral Graft versus Host Disease
LP-50 for non-muscle invasive bladder cancer
FOR PATIENTS
Oral Lichen Planus Clinical Trial
Oral Lichen Planus Registry
LP-10 for Hemorrhagic Cystitis (HC)
Radiation Cystitis Registry
MANAGEMENT
PUBLICATIONS
INVESTORS
Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact
Recent News
Stock Quote
Lipella Pharmaceuticals, Inc
2023-02-07T19:23:54+00:00
Investors
Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact
Close Sliding Bar Area
Recent Posts
A Message from Our CEO, Dr. Jonathan Kaufman
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry
Lipella Pharmaceuticals Announces Successful Completion of Pre-IND Type B FDA Meeting Regarding Oral Lichen Planus Drug Candidate
Lipella Pharmaceuticals, Inc.
Phone:
412-894-1853
Email:
Get In Touch Via Email
Reach Out
Investors
Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact
Page load link
Go to Top
Reach Out